Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) following interleukin-3 (IL-3) priming has been shown t o increase thrombopoiesis. To elucidate the comparative abilities of IL-3 and GM-CSF in influencing megakaryocyte development in vivo, serial bone marrow analyses were performed on rhesus monkeys treated with 5 pg/ kg/d of IL-3 and 5 pg/kg/d of GM-CSF sequentiallyfor 4 days each, simultaneously for 8 days, and as single agents for 8 days. Platelet counts maximally increased t o a mean of 7.5 x 105/pL ( n = 3 ) on days 11 through 12 in monkeys treated with sequential IL-3IGM-CSF. In contrast, neither IL-3 alon'e nor simultaneously administered IL-3/GM-CSF elicited increases in thrombopoiesis between days 3 and 15. GM-CSF elicited a variable platelet response. Megakaryocyte ploidy distributions were significantly (P e .001) shifted between days 7 and 10 in monkeys treated sequentially and TH THE ADVENT of cloned genes for human colony-stimulatory factors, the process of megakaryocyte growth, differentiation, and platelet production can now be examined and potentially regulated in vivo using recombinant cytokines. Although platelet-lineage-specific stimulators are as yet undefined, several other recombinant growth factors, including interleukin-3 (IL-3), granulocytemacrophage colony-stimulating factor (GM-CSF), and IL-6, have been shown to stimulate megakaryocytop~iesis.'-~ In many instances, overlapping biologic effects of these growth factors on the megakaryocyte lineage O C C U~.~-~ The actions of many hematopoietic growth factors are known to be directly mediated by binding to receptors on specific target cells or indirectly mediated through the release of secondary regulators after receptor binding on accessory cells. In the case of IL-3 and GM-CSF, evidence exists for a common high-affinity receptor on monocytes in addition to separate IL-3 and GM-CSF receptors,* suggesting one possible mechanism for their concordant effects. In fact, both IL-3 and GM-CSF stimulate megakaryocyte proliferative activity in vitro, and the lack of an additive effect using optimal cytokine concentrations has been noted by some investigators. 435 However, differences in the actions of IL-3 and GM-CSF on megakaryocytopoiesis have also been described. Additive stimulation of megakaryocyte progenitors by IL-3 and GM-CSF has been shown with cells derived from purified CD34' cell^,^.^ and IL-3 increases the frequency of megakaryocyte colonies compared with GM-CSF.I0 Recent in vivo studies in primates seem to support the concept of distinct actions on the megakaryocyte-platelet lineage by the two cytokines. In this regard, it has been shown that administration of GM-CSF alone does not result in a consistent platelet response,11-13 although administration of GM-CSF after IL-3 priming elicits increased thrombopoiesis.14 In the present study, the comparative effects of these two cytokines are shown in serial studies of megakaryocyte maturation and platelet production using IL-3 and GMbetween days 3 and 15 in monkeys treated with combined IL-B/GM-CSF and with GM-CSF alone but not in monkeys treated with IL-3 alone. The changes in mean DNA content and megakaryocyte size, as determined by digital image analysis, were larger in monkeys treated with sequential IL-B/GM-CSF and with GM-CSF alone than in simultaneously treated monkeys. In addition, sequentially but not simultaneously treated monkeys showed increased numbers of megakaryocytes on bone marrow biopsy. We conclude that administration of IL-3 followed by GM-CSF treatment increases thrombopoiesis b y sequentially increasing megakaryocyte numbers and maturation and that these effects are diminished by simultaneous administration of the two cytokines. This is a US government work. There are no restrictions on its use.
CSF administered sequentially, in combination, and as single agents. The results, which show significant differences in megakaryocyte and platelet response, should have important therapeutic implications and further clarify the potential physiologic roles of these cytokines.
MATERIALS AND METHODS

Animals.
Twelve sexually mature rhesus monkeys (Macaca mulatta) weighing between 7 and 12 kg were studied. The animals were housed at the Yerkes Regional Primate Center (Atlanta, GA) and were cared for according to the guidelines of the American Association for Accreditation of Laboratory Animal Care. Studies were approved by the Yerkes Animal Resources Committee, Emory University. Animals were anesthetized with ketamine hydrochloride during bone marrow aspirations.
Clinical side effects. No significant side effects occurred in any of the monkeys during the study. K3 EDTA vacutainers and analyzed 2 to 4 hours after venipuncture. Bone marrow aspirates, drawn in supplemented CATCH buffer containing 5% fetal calf serum, prostaglandin E1 (1.0 p,g/mL), and DNAase I (30 U/mL) (Sigma Chemical Co, St Louis, MO), were obtained pretreatment (study day 1) and on days 3, 5, 7, 9, 10, 11, 12, 15, and 22. Bone marrow biopsies were obtained from the proximal femur pretreatment and on day 9. On study days when treatment was administered, samples were obtained before the injections. Total blood loss for each monkey was approximately 10 mL/kg during the study.
GM-CSF and
Cells were processed and analyzed as previously d e~c r i b e d . '~J~ Briefly, cells were labeled with a saturating concentration of a fluorescein-conjugated mouse monoclonal antibody (CD,41) directed against human platelet glycoprotein IIb/IIIa (AMAC, Westbrook, MA). Control cells were labeled with a fluoresceinated IgGl control (Becton Dickinson, Mountain View, CA). Cells were permeabilized with 0.5% Tween 20, followed by the addition of 0.5% Tween 20 in 1% paraformaldehyde.16 DNA was labeled with propidium iodide (50 kg/mL) and then RNAase (50 kg/mL bovine pancreas) (Sigma Chemical Co) was added 30 minutes before analysis. From 0.5 to 2 X IO6 cells per bone marrow sample were analyzed at a flow rate of 1, OOO to 2,000/s on a FACScan (Becton Dickinson). Megakaryocytes were selected by excluding 99% of the control cells greater than 4N.17 DNA distributions for megakaryocytes 2 2N were measured; however, DNA ploidy distributions were analyzed for megakaryocytes r 8 N because small changes in the positioning of the green gate can significantly alter the proportions of the 2N and 4N populations.~7J8
Megakaryocyte area and DNA content were determined by digital image analysis as previously des~ribed.'~.'~ Cells were stained as described for flow cytometry. After fixation with 1% paraformaldehyde, 0.2% glutaraldehyde was added to the cell suspension just before microscopy. Wetmounted cells were examined with a Zeiss Aziovert microscope (Carl Zeiss, Inc, Oberkochen, Germany) equipped with epifluorescence. Emitted fluorescence was transmitted to a video camera and IM 3000 digital image analysis system (Analytical Imaging Concepts, Irvine, CA) containing 256 gray levels for pixel discrimination. Megakaryocytes were identified by cytoplasmic green fluorescence, and images of between 75 and 100 megakaryocytes were obtained per bone marrow sample. The average total nuclear gray per cell values on each specimen corresponding to the fluorescent intensity of the propidium iodide-stained DNA were determined using established procedure^.^^.^^ These are reported in arbitrary units as a sum of the products of the nuclear area in pixels and the average density of pixels within the nuclear area divided by the number of cells examined to give a mean total nuclear density value Studyprotocol.
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per cell, referred to as the total nuclear gray value.*l Nuclear DNA thresholds and peak levels were kept constant from sample to sample. Megakaryocyte areas are reported in square micrometers.
The absolute numbers of megakaryocytes per high-power field (X400) were enumerated on bone marrow sections stained with hematoxylin and eosin. Ten highpower fields per sample were counted. The number of megakaryocytes were also corrected for size as previously d e s~r i b e d .~~.~~ Megakaryocyte area was determined on bone marrow sections by digital image analysis.
Statistical anaiysis. Posttreatment megakaryocyte ploidy distributions were compared with ploidy distributions obtained pretreatment using the x2-test." Megakaryocyte cytoplasmic area and mean total nuclear gray values obtained pretreatment were compared with posttreatment mean values using the Student's t-test. 24 Megakaryocyte numbers were also compared using the Student's t-test. Results are reported as statistically significant if P s .05.
Megakalyocyte enumeration.
RESULTS
As has been observed by other investigator^,'^ sequential administration of IL-3/GM-CSF resulted in increases in platelet counts (Fig 1) . In this study, a mean maximum For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 2482 increase of 3.2 x 10s/pL (n = 3) occurred on study days 11 through 12, from a mean pretreatment platelet count of 4.3 x 105/pL. In contrast, neither treatment with IL-3 alone nor simultaneous administration of IL-3 and GM-CSF elicited changes in platelet counts on study days 3 through 15. Late increases in platelet counts ranging from 1.2 to 2.6 x 10s/pL were observed between days 17 and 22 in monkeys treated with IL-3 for 8 days either with or without GM-CSF. Two monkeys that were treated with single-agent GM-CSF showed a variable platelet response, consistent with our previous observations at a higher dose. 13 No changes in mean platelet volume were noted in any of the monkeys (range, 9 to 11 fL). All three GM-CSFcontaining regimens resulted in increases in white blood cells (WBCs) ranging from 18.0 x 103/pL to 68.5 X 1@/pL from pretreatment values ranging from 4.3 x 103/pL to 9.2 x 103/pL (Fig 2) .
Megakaryocyte ploidy was evaluated in bone marrow specimens by two-color flow cytometry during and after treatment. The mean percent 21 SD ploidy distribution found in normal rhesus monkeys (n = 12) before treatment was: 8N, 11.8 2 4.0; 16N, 42.7 ? 9.9; 32N, 40.7 +-8.7; 64N, 4.8 2 4.0. As shown in Fig 3, large increases in the proportion of high ploidy megakaryocytes were observed in monkeys treated with both sequential and simultaneous IL-3/GM-CSF but not when IL-3 was administered alone. Ploidy was significantly increased from pretreatment (P < .001) between days 7 and 10 in three of three monkeys that received IL-3 followed by GM-CSF and between days 3 and 15 in two of two animals treated with combined IL-3/GM-CSF, with increases in the frequency of 64N and 128N megakaryocytes observed. 128N megakaryocytes, usually not present in significant numbers in simian bone marrow specimens, were noted throughout the period of increased ploidization in monkeys treated with the two growth factors sequentially, but only on days 3 and 5 in animals treated with IL-3/GM-CSF concurrently. Neither saline-nor IL-3-treated monkeys demonstrated significant changes in ploidy distributions at any time during the study.
Digital image analysis confirmed the serial effects of IL-3 and GM-CSF on DNA content. Mean total nuclear gray values, a measure of mean cell DNA density, were maximally increased on day 5 in monkeys receiving either single-agent GM-CSF or simultaneous IL-3/GM-CSF, whereas animals treated with sequential IL-3/GM-CSF attained a peak in DNA content on day 9 (Fig 4) . IL-3, in contrast, elicited no significant increases in mean total nuclear gray values during this study. Changes in mean DNA content were smaller in monkeys treated with combined IL-3/GM-CSF compared with primates treated either with GM-CSF alone or with sequential IL-3/GM-CSF (P < .0001). Changes in mean of the DNA content obtained by digital image analysis approximated the changes in mean megakaryocyte ploidy22 calculated from flow cytometry data (Fig 4) .
Increases in megakaryocyte size approximated the increases in DNA content (Fig 5) . GM-CSF, sequential IL-3/GM-CSF, and simultaneous IL-3/GM-CSF resulted in 1.5-to 1.8-fold increases in mean megakaryocyte areas 
DISCUSSION
IL-3 and GM-CSF have been extensively shown to influence in vitro megakaryocytopoiesis in several studies.1,2,4-7*9J0 However, the nature and extent of their in vivo effects on megakaryocyte development and their potential for clinically enhancing thrombopoiesis have not been fully explained. The present study was undertaken to examine comparatively serial changes in megakaryocyte maturation elicited by IL-3 and GM-CSF and to correlate these with the platelet response. The results clearly show differing actions of the two cytokines and lend support to the concept of common effector pathways.
In this study, sequential IL-3/GM-CSF resulted in increases in platelet counts, as has been observed by other investigator^.'^.^^ Changes in platelet counts, which occurred beginning on day 9, were associated with significant
increases in megakaryocyte ploidy, noted initially on day 7, and with an increase in megakaryocyte number. No shifts in ploidy distribution were present during the IL-3 phase of the regimen. In contrast, only increases in megakaryocyte DNA content and size but not number have been observed with GM-CSF,13 and IL-3 administered alone conversely elicited increases in number but not in ploidy. These findings support the premise, primarily based on in vitro data,27-29 that distinct growth factors regulate megakaryocytopoiesis at different levels of cell development. In this study, a more optimal platelet response was achieved with serial administration of 1L-3 and GM-CSF, each affecting different stages of megakaryocytopoiesis, than occurred with either factor alone. Smaller and delayed increases in thrombopoiesis were observed after IL-3 consistent with the late stimulation of platelet counts reported in humans treated with a 2-week regimen of IL-3.30 Therefore, it is possible that sufficient increases in megakaryocyte number without increases in megakaryocyte maturation (ie, size and ploidy) eventually result in increases in platelet production. The converse, ie, increases in ploidy and size in the absence of increases in megakaryocyte number, has been associated both with single-agent GM-CSFI3 and with IL-6,15*31332 despite differing effects on platelet counts of the two Whereas with IL-6 increases in DNA content and size seem to correlate with changes in platelet levels, a similar consistency was not observed with singleagent GM-CSF.
Interestingly, simultaneous administration of IL-3 and GM-CSF, unlike the sequential regimen, did not result in changes in platelet count, despite the longer administration, and hence higher total dose, of each of the two factors. Significant increases in mean megakaryocyte DNA content, with maximum increases on day 5, did occur with simultaneous IL-3/GM-CSF. However, as shown in Fig 4, these effects were clearly diminished compared with those elicited by sequential IL-3/GM-CSF and by GM-CSF alone. In
cytokines.11-13J5333
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From addition, megakaryocyte number was unchanged after simultaneous treatment, although it was increased after both sequential IL-3lGM-CSF and IL-3 alone. The recent observation in liquid cultures that IL-3, which promotes megakaryocyte proliferation, abrogates the enhanced endoreduplication elicited by a thrombopoietin-like factor in aplastic plasma34 seems relevant to the present in vivo data. These findings lend additional support to the concept of independent regulation of megakaryocyte proliferation and maturation but at the same time suggest the possibility of partial competition between the cytokines. In vitro, reduced binding of GM-CSF to bone marrow cells in the presence of IL-3 is well d o c~m e n t e d ,~,~~-~~ with more recent evidence favoring direct interference rather than downmodulation as the basis for the observed receptor interaction^.^,^^,^ ' The results of the present study demonstrate differing effects of GM-CSF and IL-3 on megakaryocyte development in primates. Contrary to in vitro data,38 significant changes in maturation occurred only in response to GM-CSF and not to IL-3. Although the interacting physiologic roles of these cytokines in various thrombocytopenic states remains to be fully ascertained, their therapeutic usefulness in enhancing platelet production by sequentially increasing megakaryocyte numbers and maturation seems promising. The observed diminution of effects on megakaryocyte development and platelet production of simultaneously administered GM-CSF and IL-3 may indicate overlapping receptor pathways on megakaryocytes or on other target cells and provides a strong rationale for further studies on its mechanism at the cellular level.
